Peginterferon alfa-2a Pegasys - Treatment - Hepatitis C Online

Pegylated Interferons for the Treatment of Chronic Hepatitis C

Retrospective pooled safety analysis of standard- versus high-dose peginterferon alfa-2a (40KD) (PEGASYS) in chronic hepatitis C genotype 1 or 4 patients

Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease - Clinical Gastroenterology and Hepatology

Using Pegylated Interferon and Ribavirin to Treat Patients with Chronic Hepatitis C

Full article: Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial - The Lancet

Peginterferon alfa-2a Pegasys - Treatment - Hepatitis C Online

Full article: Thymalfasin for the treatment of chronic hepatitis C infection

Pegasys 180mcg Injection

Peginterferon alfa-2b PegIntron - Treatment - Hepatitis C Online

The way forward in HCV treatment — finding the right path

Pegylated interferon alfa-2b - wikidoc

Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection - ScienceDirect

Comparing Pegasys and PegIntron at EASL 2008 Milan

Peginterferon alfa-2a Pegasys - Treatment - Hepatitis C Online